Jul 2026· Research Journal of Pharmacy and Technology· Vol 19, pp. 3053· 0 citations· 17 references
Abstract
Objective: To investigate the potential pharmacological activity of β-Asarone against Paracetamol (PCM) induced hepatotoxicity. This involves screening its efficacy in preventing or treating liver damage caused by Pcm. Material and methods: The experiment involved five groups, each consisting of six rats. Group I served as the normal control, while the other four groups received an oral dose of paracetamol (2000mg/kg) to induce toxicity. Group III was treated with the standard drug silymarin (100mg/kg), and Groups IV and V received β-asarone at doses of 25mg/kg and 50mg/kg, respectively. All treatments were administered orally for 10 consecutive days. At the end of the study, the animals were humanely sacrificed, and blood and liver samples were collected for further analysis. Results and discussion: Based on acute oral toxicity screening, a non-lethal dose of β-asarone was established at 221mg/kg. Doses of 25mg/kg and 50mg/kg were selected for the study. High doses of paracetamol caused significant liver damage, as shown by elevated liver enzymes (AST, ALT) and bilirubin, and decreased protein levels. Both silymarin and β-asarone treatments effectively prevented these changes. The higher dose of β-asarone (50mg/kg) showed a more pronounced protective effect, closely resembling the healthy liver tissue and outperforming both the lower dose and the standard silymarin treatment in reducing liver inflammation and damage. Conclusion: β-asarone protects against paracetamol-induced liver damage, with the 50mg/kg dose proving most effective at normalizing liver enzymes and preserving liver structure.
Paracetamol-induced hepatotoxicity is characterized by oxidative stress, inflammatory responses, and progressive liver
damage. The present study aimed to evaluate the hepatoprotective effects of Serinolamide A against paracetamol-induced
hepatotoxicity in rats. Experimental hepatotoxicity was induced by paracetamol administration, and rats were treated
orally with Serinolamide A (1, 5, and 10 mg/kg) for 28 consecutive days. Liv52 (70 mg/kg, p.o.) was used as the standard
drug. Body weight, liver weight, serum biochemical parameters, oxidative stress markers, pro-inflammatory cytokines,
and histopathological changes were evaluated. Treatment with Serinolamide A significantly ameliorated paracetamolinduced alterations and restored body and liver weights. Furthermore, Serinolamide A enhanced antioxidant defense by
increasing superoxide dismutase, catalase, and reduced glutathione activities and reduced lipid peroxidation. The
treatment also attenuated inflammatory responses by decreasing tumor necrosis factor-α and interleukin-6 levels.
Histopathological examination revealed marked protection against paracetamol-induced hepatic damage. The observed
effects were dose-dependent, with the 10 mg/kg dose showing effects comparable to those of Liv52. These findings
suggest that Serinolamide A possesses significant hepatoprotective activity, which may be attributed to its antioxidant and
anti-inflammatory properties, and could represent a promising therapeutic candidate for the management of drug-induced
liver injury
Prajita J. Tayade, Sujal R. Jaiswal, Sayli A. Tekade et al.· International Journal of Dru...· 0 citations
Similar to viral hepatitis in humans, paracetamol causes liver damage. Recent developments indicate that traditional plants have been used to treat hepatotoxicity. The current study has been performed to investigate the effectiveness of Lannea coromandelica (LC) bark in reducing the hepatotoxicity caused by paracetamol in rats due to its application in folk medicine. Rats (150–200 g) were split up into 5 groups (n=6). Paracetamol (600 mg/kg body weight) was given once daily for a week, causing acute hepatotoxicity, while the plant extract under investigation was taken orally at 250 and 500 mg/kg body weight for the duration of the experiment. As is customary for hepatoprotective medications, silymarin (100 mg/kg b.w.) was administered orally. Hepatoprotection was ascertained by estimating biochemical indicators such as ALT, AST, ALP, total protein, albumin and globulin level.Treatment with LC extracts significantly attenuated the increased plasma levels of ALT (p<0.05), AST (p<0.05) and ALP (p<0.001) level whereas insignificantly improved total protein, albumin and globulin level. The extract insignificantly progressed the body weight and significantly increased the liver weight (p<0.05) as compared to the disease control animals. The estimated biomarkers provide evidence that the Lannea coromandelica bark extract has shown hepatoprotective activity against paracetamol induced hepatotoxicity in rats.
Bangladesh Pharmaceutical Journal 29(2): 254-260, 2026 (July)
Md Rashed Hossen, Khaleda Nahid, M. Rahman et al.· Bangladesh Pharmaceutical Jo...· 0 citations
Under the present experimental conditions, FVMF was not supported as a candidate for managing hepatorenal injury; its reported cytotoxic and anticancer activities require separate evaluation.
Okwulu O. J., R. A. Oguntoye, I. Lawal et al.· International Journal of Bio...· 0 citations
Rosmarinus officinalis extract may exert protective effects against MTX-induced hepatorenal injury through antioxidant and anti-inflammatory mechanisms, however, further studies are required to confirm these effects and validate their therapeutic potential.
Lana Muhammed, Nadia Salih· Open Veterinary Journal· 0 citations
The AETP flower extract demonstrates dosedependent protective effects on the liver against PCM-induced liver injury, likely attributed to its antioxidant and anti-inflammatory phytochemicals.
Abhishek Bhattacharjee, P. Paul, Sumana Majumder et al.· Journal of Clinical and Diag...· 0 citations
